TG Therapeutics, Inc. Announces Clinical Data Presentations

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 51st Annual Meeting of the American Society of Clinical Oncology

The Triple-Combination Therapy of TG-1101, TGR-1202, and ibrutinib to be Highlighted in an Oral Presentation

Updates on the Combination of TG-1101 Plus TGR-1202, and Single-Agent TGR-1202 to be Featured in Poster Presentations

NEW YORK, May 13, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX ), today announced that updated data for TG-1101 (ublituximab), the Company's novel, glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, the Company's PI3K delta inhibitor, has been selected for presentation at the upcoming 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from May 29 – June 2, 2015, at McCormick Place in Chicago, Illinois.

The presentation schedule at ASCO 2015 is as follows:

Oral Presentation:

  • Title: Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies
    • Abstract Number: 8501
    • Presentation Date & Time: Monday, June 1, 2015, 9:57AM – 10:09AM CT
    • Session Type/Track: Oral Abstract Session/ Lymphoma and Plasma Cell Disorders
    • Presenter: Nathan H. Fowler, MD, University of Texas MD Anderson Cancer Center

Poster Presentations:

  • Title: Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL
    • Abstract Number: 8548
    • Presentation Date & Time: Sunday, May 31, 2015, 8:00AM – 11:30AM CT
    • Track: Lymphoma and Plasma Cell Disorders
    • Presenter: Matthew A. Lunning, DO, University of Nebraska Medical Center
  • Title: Clinical activity and safety profile of TGR-1202, a novel once daily PI3K delta inhibitor, in patients with CLL and B-cell lymphoma
    • Abstract Number: 7069
    • Presentation Date & Time: Sunday, May 31, 2015, 8:00AM – 11:30AM CT
    • Track: Leukemia, Myelodysplasia, and Transplantation
    • Presenter: Howard A. Burris, MD, Sarah Cannon Research Institute, Tennessee Oncology, PLLC

A copy of the ASCO abstracts were made available today, May 13, 2015 at 5:00pm ET through the ASCO meeting website at www.asco.org . Following each presentation, the date presented will be available on the Publications page, located within the Pipeline section, of the Company's website at www.tgtherapeutics.com .

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G

Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading